MoonLake Immunotherapeutics
MLTX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001821586
In the last 90 days, MoonLake Immunotherapeutics insiders filed 0 open-market purchases and 5 sales; 172 institutions reported holding it in 13F filings for Q2 2026, worth $1.43B in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding MoonLake Immunotherapeutics changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 33 | 43 | +10 |
| Shares | 37.7M | 39.4M | +1.67M (+4.4%) |
| Value | $396.4M | $843.2M | +$446.8M (+112.7%) |
New holders (21)
Institutions that held MoonLake Immunotherapeutics at the end of Q1 2023 but not at the end of Q4 2022.
Sold out (11)
Institutions that held MoonLake Immunotherapeutics at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| TCG Crossover Management, LLC | 1,000,000 | $10.5M |
| Braidwell LP | 381,120 | $4.00M |
| Tekla Capital Management LLC | 300,000 | $3.15M |
| Tang Capital Management LLC | 245,714 | $2.58M |
| Acuta Capital Partners, LLC | 93,500 | $981.8K |
| Barclays PLC | 55,952 | $587.5K |
| Cheyne Capital Management (UK) LLP | 32,129 | $337.4K |
| Meridian Wealth Management, LLC | 15,000 | $154.3K |
| Virtu Financial LLC | 14,395 | $151.0K |
| Two Sigma Investments, LP | 12,385 | $130.0K |
| Goldman Sachs Group Inc | 10,110 | $106.2K |